Crottogini A J, Depaoli J R, Barra J G, Fischer E C, Rodríguez Chatruc M, Pichel R H, de la Fuente L
Am Heart J. 1985 Oct;110(4):753-60. doi: 10.1016/0002-8703(85)90453-3.
The effect of the new calcium antagonist nisoldipine (BAY k-5552) on myocardial infarct size was studied in four groups of conscious dogs undergoing acute left anterior descending coronary artery occlusion. Group I received placebo for 48 hours before and for 24 hours after occlusion; group II received placebo before and nisoldipine (0.3 mg/kg orally every 6 hours) after occlusion; group III received nisoldipine before and placebo after occlusion; and group IV received nisoldipine before and after occlusion. Infarct size was quantified with the tetrazolium red staining technique. Infarcted ventricular mass was 24.5 +/- 6.6% (mean +/- SD) for group I (control), 21.4 +/- 4.4% for group II (p = NS against control), 13.9 +/- 4.5% for group III (p less than 0.05), and 14.1 +/- 4.0% for group IV (p less than 0.05). Post occlusion sudden death was 30% in non-pretreated dogs and 0% in pretreated dogs (p less than 0.001). We conclude that prophylactic oral treatment with nisoldipine decreases infarct size and lowers the incidence of sudden death in conscious dogs undergoing acute coronary occlusion.
在四组清醒犬中研究了新型钙拮抗剂尼索地平（BAY k - 5552）对急性左前降支冠状动脉闭塞后心肌梗死面积的影响。第一组在闭塞前48小时和闭塞后24小时接受安慰剂；第二组在闭塞前接受安慰剂，闭塞后接受尼索地平（每6小时口服0.3mg/kg）；第三组在闭塞前接受尼索地平，闭塞后接受安慰剂；第四组在闭塞前后均接受尼索地平。采用四氮唑红染色技术对梗死面积进行定量分析。第一组（对照组）梗死心室质量为24.5±6.6%（均值±标准差），第二组为21.4±4.4%（与对照组相比，p = 无显著差异），第三组为13.9±4.5%（p＜0.05），第四组为14.1±4.0%（p＜0.05）。闭塞后，未预处理犬的猝死率为30%，预处理犬的猝死率为0%（p＜0.001）。我们得出结论，尼索地平预防性口服治疗可减小清醒犬急性冠状动脉闭塞后的梗死面积并降低猝死发生率。
